{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2016-06-06&answeringDeptId=17&tablingMemberConstituency=Stafford&answeringDeptSortName=Health+and+Social+Care&max-answer.questionFirstAnswered.=2018-09-11T14%3A35%3A39.31Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?min-answer.dateOfAnswer=2016-06-06&answeringDeptId=17&tablingMemberConstituency=Stafford&answeringDeptSortName=Health+and+Social+Care&max-answer.questionFirstAnswered.=2018-09-11T14%3A35%3A39.31Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2016-06-06&answeringDeptId=17&tablingMemberConstituency=Stafford&answeringDeptSortName=Health+and+Social+Care&_metadata=all&max-answer.questionFirstAnswered.=2018-09-11T14%3A35%3A39.31Z", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2016-06-06&_page=0&answeringDeptId=17&tablingMemberConstituency=Stafford&answeringDeptSortName=Health+and+Social+Care&max-answer.questionFirstAnswered.=2018-09-11T14%3A35%3A39.31Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2016-06-06&answeringDeptId=17&tablingMemberConstituency=Stafford&answeringDeptSortName=Health+and+Social+Care&max-answer.questionFirstAnswered.=2018-09-11T14%3A35%3A39.31Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2016-06-06&answeringDeptId=17&tablingMemberConstituency=Stafford&answeringDeptSortName=Health+and+Social+Care&max-answer.questionFirstAnswered.=2018-09-11T14%3A35%3A39.31Z", "items" : [{"_about" : "http://data.parliament.uk/resources/964650", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/964650/answer", "answerText" : {"_value" : "
The Accelerated Access Collaborative will meet this autumn to launch the Accelerated Access Pathway and the first group of products will be part of their discussions.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-09-11", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-09-11T14:35:39.31Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-09-03", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Medical Treatments: Innovation"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, when the accelerated access pathway is planned to begin designating breakthrough products.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4109", "label" : {"_value" : "Biography information for Jeremy Lefroy"} } , "tablingMemberConstituency" : {"_value" : "Stafford"} , "tablingMemberPrinted" : [{"_value" : "Jeremy Lefroy"} ], "uin" : "169361"} , {"_about" : "http://data.parliament.uk/resources/882155", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/882155/answer", "answerText" : {"_value" : "
Informal discussions have already begun with industry regarding future medicines pricing arrangements. Formal negotiations will begin shortly.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-04-19", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-04-19T11:28:11.54Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-04-13", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Pharmaceutical Price Regulation Scheme"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what the timetable for negotiations on the new pharmaceutical price regulation scheme is; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4109", "label" : {"_value" : "Biography information for Jeremy Lefroy"} } , "tablingMemberConstituency" : {"_value" : "Stafford"} , "tablingMemberPrinted" : [{"_value" : "Jeremy Lefroy"} ], "uin" : "135214"} , {"_about" : "http://data.parliament.uk/resources/882668", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/882668/answer", "answerText" : {"_value" : "
The Government has noted the importance of continued collaboration with European partners in the 2017 policy paper \u2018Collaboration on Science and Innovation: A Future Partnership Paper\u2019. European Reference Networks (ERNs) for rare diseases patients were cited in the paper as an example of collaboration that the United Kingdom and European Union should discuss in the negotiations, given the mutual benefit.<\/p>
<\/p>
The Government has set out three key principles in developing a new regulatory system post EU exit: patients should not be disadvantaged; innovators should be able to get their products into the UK market as quickly and simply as possible; and we continue to play a leading role promoting public health. The Government will be guided by these principles in its negotiations with EU partners.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"} } , "answeringMemberConstituency" : {"_value" : "Gosport"} , "answeringMemberPrinted" : {"_value" : "Caroline Dinenage"} , "dateOfAnswer" : {"_value" : "2018-04-19", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-04-19T14:12:32.767Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-04-13", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Rare Diseases"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether the Government plans to continue to participate in the European Reference Networks for patients with complex or rare medical conditions after the UK leaves the EU and the expiry of the implementation period.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4109", "label" : {"_value" : "Biography information for Jeremy Lefroy"} } , "tablingMemberConstituency" : {"_value" : "Stafford"} , "tablingMemberPrinted" : [{"_value" : "Jeremy Lefroy"} ], "uin" : "135730"} , {"_about" : "http://data.parliament.uk/resources/873628", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/873628/answer", "answerText" : {"_value" : "
The National Institute for Health and Care Excellence (NICE) quality standards are concise sets of statements designed to drive quality improvements within a particular area of care and cover the National Health Service, public health and social care. They are derived from the best available evidence, normally NICE guidance but also other sources of NICE-accredited guidance, and are developed by NICE in collaboration with health and social care professionals, their partners and service users. The Department does not have any arrangements for monitoring the uptake of NICE quality standards centrally as they are not mandatory, although health and care commissioners are expected to take them fully into account.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-04-17", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-04-17T14:04:58.22Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-03-28", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Spondyloarthritis"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure the monitoring of individual Quality Statement measures in the NICE Quality Standard on Spondyloarthritis, to be published in June 2018.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4109", "label" : {"_value" : "Biography information for Jeremy Lefroy"} } , "tablingMemberConstituency" : {"_value" : "Stafford"} , "tablingMemberPrinted" : [{"_value" : "Jeremy Lefroy"} ], "uin" : "134742"} , {"_about" : "http://data.parliament.uk/resources/873629", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/873629/answer", "answerText" : {"_value" : "
In August 2017, a new three year Rheumatoid and Early Inflammatory Arthritis Audit was commissioned by the Healthcare Quality Improvement Partnership (HQIP). HQIP manages the National Clinical Audit and Patient Outcomes Programme on behalf of NHS England.<\/p>
<\/p>
The British Society for Rheumatology was awarded the contract to run the audit, which will assess the care provided by rheumatology services in England and Wales, and the health outcomes this achieves for people living with inflammatory arthritis conditions, including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis.<\/p>
<\/p>
Building on the previous audit, which ran from 2014-16, it will provide more focused and precise data and employ real-time feedback to support local quality improvement. The audit is expected to launch in May this year, with first reports expected in the autumn of 2019. More information can be found at the following link:<\/p>
<\/p>